title: Severe cholestasis due to disseminated histoplasmosis under adalimumab-containing immunosuppressive therapy.
authors.forename: Berend J
authors.initials: BJ
authors.lastname: van Welzen
authors.forename: Karel J
authors.initials: KJ
authors.lastname: van Erpecum
authors.forename: Pieter-Jan A
authors.initials: PJ
authors.lastname: Haas
authors.forename: Fiebo J
authors.initials: FJ
authors.lastname: ten Kate
authors.forename: Tania
authors.initials: T
authors.lastname: Mudrikova
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002779:Cholestasis / Q000139:chemically induced* / Q000382:microbiology*; D005260:Female; D006660:Histoplasmosis / Q000150:complications*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D012720:Severity of Illness Index
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000068879:Adalimumab